Quotient Ltd. (NASDAQ:QTNT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Shares of Quotient (NASDAQ:QTNT) opened at 7.44 on Wednesday. The stock’s market cap is $106.96 million. The company’s 50-day moving average is $7.40 and its 200-day moving average is $8.26. Quotient has a 52-week low of $5.67 and a 52-week high of $17.44.
In other Quotient news, Director L John Wilkerson acquired 180,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was purchased at an average price of $5.50 per share, for a total transaction of $990,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider D J. Paul E. Cowan acquired 45,455 shares of the company’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was acquired at an average price of $5.50 per share, with a total value of $250,002.50. Following the acquisition, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $146,663. The disclosure for this purchase can be found here. Company insiders own 40.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in QTNT. Geode Capital Management LLC acquired a new position in shares of Quotient during the first quarter worth $105,000. First New York Securities LLC NY acquired a new position in shares of Quotient during the second quarter worth $140,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Quotient during the first quarter worth $172,000. BlackRock Investment Management LLC boosted its position in shares of Quotient by 2.5% in the second quarter. BlackRock Investment Management LLC now owns 86,418 shares of the company’s stock worth $670,000 after buying an additional 2,075 shares during the period. Finally, Bellevue Group AG acquired a new position in shares of Quotient during the first quarter worth $880,000. Hedge funds and other institutional investors own 41.50% of the company’s stock.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.